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ABSTRACT
Objectives: Ankylosing spondylitis (AS) is associated
with increased cardiovascular morbidity and mortality.
Microvascular function has been linked to several risk
factors for cardiovascular disease. Inflammation in AS
may cause microvascular dysfunction. To test this, we
assessed microvascular function in (a) patients with AS
compared to healthy controls and (b) patients with AS
before and after 1 month of anti-tumour necrosis factor
(TNF)a treatment with etanercept.
Methods: A total of 15 consecutive patients with AS,
who were scheduled for etanercept treatment according
to the Assessment in Ankylosing Spondylitis (ASAS)
group guidelines, and 12 healthy controls matched for age
and sex, were recruited. Endothelium-dependent and
independent vasodilatation in skin were evaluated with
laser Doppler fluxmetry after iontophoresis of acetylcho-
line and sodium nitroprusside, respectively.
Videomicroscopy was used to measure recruitment of
skin capillaries after arterial occlusion.
Results: Compared to healthy controls, patients with AS
had impaired endothelium-dependent vasodilatation and
capillary recruitment. Following anti-TNFa treatment,
microvascular function improved significantly for
endothelium-dependent vasodilatation (p = 0.03) and
capillary recruitment (p = 0.006). A significant correlation
was observed between changes in endothelium-depen-
dent vasodilatation and changes in erythrocyte sedimen-
tation rate (ESR) (r =20.56; p = 0.03).
Conclusion: Microvascular dysfunction is present in
patients with AS with active disease, but improves as
inflammation regresses after TNFa blockade.
Ankylosing spondylitis (AS) is a chronic inflam-
matory disease of the sacroiliac joints and spine
affecting up to 1% of the population.1 Patients
with AS have an approximately twofold increased
death rate compared to the general population,
which is predominately caused by increased
cardiovascular (CV) risk.2–4 Although specific car-
diovascular disorders (valvular disease and conduc-
tion disturbances) occur more frequently in AS,4 5
accelerated atherosclerotic disease probably con-
tributes to the increased CV risk as well.6 7
Accelerated atherosclerosis in AS may partly be
due to traditional CV risk factors (ie, an athero-
genic lipid profile and hypertension).8 9 In addition,
the generalised inflammatory state that charac-
terises active AS renders these patients more prone
to develop cardiovascular, atherosclerotic, disease
(CVD), as many parallels exist between the
inflammatory mechanisms in the pathogenesis of
atherosclerosis and in the pathogenesis of auto-
immune diseases.10 Therefore, AS could be an
independent cardiovascular risk factor.6 7 The
association between inflammation and atherogen-
esis is most extensively described for rheumatoid
arthritis (RA) and systemic lupus erythaemato-
sus11–14 but appears to apply to AS as well.6 7
Analogous to RA,15 inflammation in AS may
cause (microvascular) endothelial dysfunction.
Endothelial dysfunction precedes and initiates
atherosclerosis and is a predictor of long-term
cardiovascular risk.16 A pivotal proinflammatory
cytokine is tumour necrosis factor a (TNFa).
Circulating TNFa levels are increased in patients
with AS and important in the pathogenesis of
AS.17 18 Increased TNFa levels may have an
important role in the pathogenesis of endothelial
dysfunction in inflammatory diseases.19–21
A particularly interesting type of vascular
dysfunction occurs in the microvasculature.
Microvascular dysfunction is closely, and presum-
ably causally, linked to CV risk factors, particularly
insulin resistance and hypertension.22 23 Preliminary
evidence suggests that inflammation may also
cause dysfunction of the microvasculature.
Impaired coronary microvascular function was
recently found in patients with AS, and correlated
well with serum C-reactive protein (CRP) and
TNFa levels.19 Interestingly, circulating levels of
CRP and TNFa are associated with skin micro-
vascular dysfunction even in normal subjects.24 25
Considering this, we hypothesised that patients
with active AS have impaired microvascular func-
tion. In addition, we anticipate that blocking
TNFa in these patients not only reduces disease
activity,26–29 but also improves microvascular func-
tion. To test this, we assessed capillary density and
recruitment as well as endothelium-(in)dependent
vasodilatation of skin microcirculation in (a)
patients with AS compared to healthy controls
and (b) patients with AS before and after 1 month
of anti-TNFa treatment with etanercept.
PATIENTS AND METHODS
Subjects
A total of 15 consecutive patients with AS (10
males), scheduled for etanercept treatment accord-
ing to the Assessment in Ankylosing Spondylitis
(ASAS) group guidelines for anti-TNFa treatment30
were studied. All patients fulfilled the modified
New York diagnostic criteria of AS31 and were
recruited from the Jan van Breemen Institute and
VU University Medical Center and treated with
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twice weekly 25 mg etanercept subcutaneously. Exclusion
criteria were (self-reported) diabetes mellitus, Raynaud phe-
nomenon, thyroid dysfunction, previous cardiovascular events,
hypertension (systolic blood pressure .140 mmHg and/or
diastolic blood pressure .90 mmHg) or the use of antihyper-
tensive agents. A total of 12 age-matched and sex-matched
healthy volunteers (8 males) served as controls. One patient and
one control subject used a statin. No alterations in (concomi-
tant) medication use, including non-steroidal anti-inflamma-
tory drugs (NSAIDs), which all patients used, were allowed
during the treatment period. All participants gave written
informed consent and the study protocol was approved by the
Institutional Ethics Committee of both hospitals.
Study design
Microvascular measurements were conducted in a quiet,
temperature-controlled room (T = 23.4¡0.4uC) after 20–
30 min of acclimatisation, with the subjects in the sitting
position and the investigated, non-dominant hand at heart
level. Nailfold capillary studies and iontophoresis studies were
performed on the same day. Subjects were asked to refrain from
beverages other than water (especially no caffeine or alcohol),
smoking, medication, except paracetamol if necessary, and
meals from midnight on the testing day. During the tests, skin
temperature was monitored and all subjects were studied
between 8.00 am and 12.00 am.
Nailfold capillaries in the dorsal skin of the third finger were
visualised by a capillary microscope (Nikon, Amstelveen, The
Netherlands), linked to a television camera (Philips LDH 0702/
20; Eindhoven, The Netherlands), a video recorder (Panasonic
NV-HS930, S-VHS; ’s-Hertogenbosch, The Netherlands) and a
monitor (Sony SSM-125CE; Badhoevedorp, The Netherlands).32
Incident illumination was achieved by light from a 100-W
vapour mercury lamp (which passes through a heat-absorption
and heat-reflection filter), a polariser and a 50% mirror to
illuminate the object. To visualise the capillaries, a 56objective
(Nikon 5/0.13) was used with a total system magnification of
1156. Nailfold capillaries in finger skin were recorded on
videotape before and after 4 min of arterial occlusion with a
digital cuff. This procedure was performed twice, and the mean
of both measurements was used for analyses. Counting was
performed using monitor (Sony PVM-1443MD) and video
recorder (Sony S-VO-9500MDP). Capillaries were counted by
a single observer using the naked eye from a freeze-framed
reproduction of the videotape, and from the running videotape
when it was uncertain whether a capillary was present or not.
We estimated baseline capillary density by counting the number
of continuously erythrocyte-perfused capillaries during a 15-s
period. Other capillaries can be seen to be intermittently
perfused, and these may represent an important functional
reserve. We used postocclusive reactive hyperemia to estimate
this functional reserve. Postocclusive capillary recruitment was
calculated by dividing the increase in density by the baseline
density. The day-to-day coefficient of variation (CoV) of the
capillary density in resting state was 2.3 (1.8)%. The CoV of the
percentage capillary recruitment and absolute capillary recruit-
ment during postocclusive hyperaemia were 8.3 (4.9)% and 6.2
(4.3)%, respectively.
Endothelium-(in)dependent vasodilatation of finger skin
microcirculation was evaluated by iontophoresis of acetylcho-
line (ACh) and sodium nitroprusside in combination with laser
Doppler fluxmetry as previously described in more detail.22 33
Laser Doppler fluxmetry measures microvascular perfusion, the
product of red blood cell velocity and concentration.34 A
protocol of multiple fixed doses (current intensity 6 delivery
time) was employed resulting in an incremental dose-response
curve. Acetylcholine (1%, Miochol-E, The´a Pharma NV,
Zoetemeer, The Netherlands) was delivered with an anodal
current; seven doses (0.1 mA for 20 s) were delivered, with a 60-
s interval between each dose. A 60-s interval between each
iontophoresis period was required to achieve the plateau of the
response following each delivery of acetylcholine.35 Sodium
nitroprusside (0.01%, VU University Medical Center (VUmc))
was delivered with a cathodal current; nine doses (0.2 mA for
20 s) were delivered, with a 90-s interval between each dose. A
90-s interval between each iontophoresis period was required to
achieve the plateau of the response after each delivery of sodium
nitroprusside.35 Acetylcholine-dependent laser Doppler flux was
measured on the middle phalanx of the third finger, whereas
nitroprusside-dependent laser Doppler flux was measured at the
same spot on the opposite hand, with approximately 15 min
elapsed between the two measurements. The day-to-day CoV
of the percentage increase from baseline to the final 2 min of the
plateau phase was 9.8 (5.6)% for acetylcholine and 8.3 (5.4)%
for sodium nitroprusside.
Statistical analyses
Data are expressed as mean (SD) or median (interquartile range)
as appropriate. The distribution of variables was tested for
normality and transformed if necessary. Variables were tested
(a) unpaired for comparing patients and controls and (b) paired
Table 1 Baseline characteristics of the patients with ankylosing
spondylitis (AS) and healthy control subjects
AS (n = 15) Controls (n = 12)
Age, years 40 (10) 40 (13)
Male, % 73 67
Disease duration, years 10.8 (8.3)
Smoking, % 47 42
Systolic blood pressure, mmHg 122 (8) 123 (11)
Diastolic blood pressure, mmHg 77 (5) 77 (5)
Pulse pressure, mmHg 44 (7) 46 (9)
Body mass index 26.9 (24.2–28.2) 23.2 (22.2–24.9)
Data are mean (SD) or median (interquartile range); Student t test or Mann–Whitney U
test were used for comparing continuous variables. The Fisher exact test was used for
dichotomous variables. Pulse pressure = systolic blood pressure–diastolic blood
pressure.
Table 2 Characteristics of patients with ankylosing spondylitis at
baseline (AS pre) and after 1 month etanercept treatment (AS post)
AS pre (n = 15) AS post (n = 15) p Value
ESR, mm/h 19 (5–45) 4 (1–13) 0.001
CRP, mg/dl 14 (4–37) 3 (1–8) 0.006
BASDAI 6.0 (5.3–7.2) 4.4 (1.8–6.4) 0.004
BASFI 5.2 (4.0–6.3) 3.2 (1.7–5.1) 0.003
BASMI 3.0 (2.0–4.0) 2.0 (2.0–4.0) 0.3
Total cholesterol, mmol/
litre
5.0 (0.7) 5.3 (0.8) 0.04
HDL, mmol/litre 1.3 (0.4) 1.4 (0.3) 0.05
LDL, mmol/litre 3.1 (0.7) 3.2 (0.7) 0.6
TG, mmol/litre 1.3 (0.7) 1.6 (1.0) 0.3
Data are mean (SD) or median (interquartile range). Lipid profile was available for 13
patients (non-fasting). Figures in bold represent significant results.
BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing
Spondylitis Functional Index; BASMI, Bath Ankylosing Spondylitis Metrology Index;
CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; HDL, high-density
lipoprotein; LDL, low-density lipoprotein; TG, triglyceride.
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for comparing the patients with AS at baseline and at 1 month.
The Student t test was used to compare continuous normally
distributed variables. We used non-parametric tests (Wilcoxon
signed-rank test or Mann–Whitney U test) when appropriate.
Linear regression analysis was used to investigate confounding
by body mass index (BMI; as calculated using the formula
weight (kg)/length (m)26100). A two-tailed probability value of
p,0.05 was considered statistically significant. Correlations
between variables were analysed by using Pearson correlation or
Spearman rho tests when appropriate.
RESULTS
Characteristics
Baseline characteristics of patients and controls are shown in
tables 1 and 2. Age, sex, blood pressure and smoking status were
similar in both groups. BMI was higher in patients compared to
controls, 26.9 (24.2–28.4) vs 23.2 (22.2–24.9) respectively
(p = 0.06). Within patients, BMI and blood pressure remained
stable between the two time points. During treatment, CRP
and erythrocyte sedimentation rate (ESR) levels, as well as Bath
Ankylosing Spondylitis Disease Activity Index (BASDAI)
decreased significantly.
Microvascular function is disturbed in AS
At baseline, patients with AS showed a markedly lower
vasodilatation in response to acetylcholine compared to controls
(118% vs 469%, respectively, p = 0.02; table 3 and fig 1). The
response to sodium nitroprusside did not differ significantly
between patients at baseline and 1 month and controls.
Baseline capillary density did not differ between groups.
However, absolute and relative postischaemic capillary recruit-
ment were lower in AS at baseline compared to controls (14.8 vs
19.5, respectively for absolute increase, p = 0.04 and 29.6% vs
39.2%, respectively for relative increase, p = 0.01). These results
remained after separately adjusting for the difference in BMI
and the difference in smoking status between the two groups
(data not shown).
Etanercept improves microvascular dysfunction
After 1 month of treatment with etanercept, endothelium-
dependent vasodilatation improved significantly in the patients
with AS (from 118% to 318%, p = 0.03; table 3 and fig 1) and
approached values observed in the healthy controls (p = 0.5).
Capillary recruitment improved significantly in patients with
AS during treatment (from 29.6% to 38.9%, p = 0.006; table 3)
to a level comparable to controls (38.9% vs 39.2%, respectively,
p = 1.0).
Etanercept-induced changes in endothelium-dependent vaso-
dilatation correlated inversely with changes in ESR levels
(r =20.56 p = 0.03, fig 2). We did not find any significant
correlations between pretreatment and post-treatment differ-
ences in endothelium-dependent vasodilatation relative to CRP
(r =20.24 p = 0.4, fig 2) or BASDAI (r =20.16 p = 0.6).
Changes in capillary recruitment (percentage) were not
significantly correlated with changes in ESR, CRP or BASDAI
(r =20.15 p = 0.6, r = 0.014 p = 1.0, r = 0.50 p = 0.06 respec-
tively), although there was a trend for BASDAI.
DISCUSSION
The present study demonstrates that patients with active AS
have impaired microvascular endothelium-dependent vasodila-
tation and capillary recruitment in skin, which improves after
TNFa-blocking therapy with etanercept.
Figure 1 Perfusion changes in response to iontophoresis of
acetylcholine in the patients with ankylosing spondylitis (AS) prior to
treatment and post treatment and in the healthy control subjects.
Baseline perfusion was set to 0% and every subsequent dot represents
the percentage perfusion change compared to baseline. Every dot
represents the median perfusion value of the 60 s between two
subsequent pulses as described in the Patients and methods section.
Table 3 Microvascular measurements
Controls (n = 12) AS pre (n = 15) AS post (n = 15) p Value (1) p Value (2) p Value (3)
ACh-mediated vasodilatation:
Skin temperature, uC 30.6 (1.3) 30.6 (1.0) 31.0 (1.4) 0.8 0.4 0.4
Baseline skin perfusion, PU 21.9 (10.8) 21.9 (7.5) 24.3 (11.5) 1.0 0.4 1.0
ACh-mediated vasodilatation, % 469 (174–692) 118 (43–288) 318 (37–591) 0.02 0.03 0.5
SNP-mediated vasodilatation:
Skin temperature, uC 30.2 (1.1) 30.4 (1.0) 31.5 (2.6) 0.7 0.2 0.2
Baseline skin perfusion, PU 17.8 (10.5) 18.7 (7.8) 23.1 (9.2) 0.7 0.07 0.2
SNP-mediated vasodilatation, % 391 (152–1116) 348 (81–649) 200 (73–401) 0.1 0.3 0.05
Capillary recruitment
Skin temperature, uC 30.3 (0.9) 30.4 (1.4) 30.7 (1.5) 1.0 0.2 0.4
Baseline capillary density, n/mm2 49.0 (6.9) 50.6 (13.4) 53.3 (11.0) 0.7 0.1 0.3
Peak capillary density, n/mm2 68.5 (12.7) 65.4 (16.8) 73.9 (15.9) 0.6 0.003 0.4
Absolute increase, n/mm2 19.5 (6.5) 14.8 (5.2) 20.7 (6.7) 0.04 0.001 0.7
Capillary recruitment, % 39.2 (9.0) 29.6 (9.3) 38.9 (10.9) 0.01 0.006 1.0
Data are mean (SD) or median (Interquartile range); p values were calculated: (1) AS pre vs controls; (2) AS pre vs AS post; (3) AS post vs controls. Bold type indicates signficance.
ACh, acetylcholine; AS, ankylosing spondylitis; SNP, sodium nitroprusside; PU, perfusion units.
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Recent advances have highlighted the crucial involvement of
the microcirculation in many cardiovascular conditions, not
only in the development of target organ damage in the heart
and kidney, but also in the development of cardiovascular risk
factors such as hypertension and insulin resistance.23 36 37
Impaired microvascular endothelium-dependent vasodilatation
and capillary recruitment, as measured in the present study,
have been linked to several conditions associated with CVD,
such as hypertension, insulin resistance and (visceral) obe-
sity.22 23 25 33 Furthermore, impaired endothelium-dependent
vasodilatation and capillary recruitment can be detected in
individuals at increased coronary heart disease (CHD) risk
according to the Framingham Heart Study risk score.38 The
cutaneous microcirculation is a representative vascular bed to
examine the mechanisms of microvascular dysfunction, which
may mirror generalised systemic vascular dysfunction in
magnitude and underlying mechanisms.39
The finding of impaired microvascular function in patients
with AS is concordant with a previous study demonstrating
impaired coronary microvascular function in patients with AS
without any overt cardiovascular disease.19 Interestingly, in the
latter study, impaired coronary microvascular function correlated
well with CRP and TNFa levels, suggesting a detrimental effect of
inflammation on the microcirculation.19 Our findings support this
hypothesis by showing, for the first time, that blocking TNFa
with etanercept, results in improvement of microvascular
endothelium-dependent vasodilatation and even a normalisation
of capillary recruitment in patients with AS compared to healthy
controls. In patients with RA, the ability of TNFa-blocking
therapies to improve endothelial function has already been
demonstrated, predominately at the macrovascular level, as
measured by brachial artery ultrasonography20 21 or plethysmo-
graphy.40 Again, in patients with RA, a case of diffusely impaired
myocardial perfusion in the absence of any significant coronary
atheroma in active systemic RA was described, which improved
following intensive immunosuppression.41 Moreover, impaired
endothelium-dependent vasodilatation has been shown at the
microvascular level during active disease (‘‘flare’’), which
improved after inflammatory suppression with disease-modifying
antirheumatic drugs (DMARDs) or TNFa-blocking therapy.42
In this regard, the observation of a lower incidence of first
cardiovascular events in patients with RA treated with TNFa-
blocking therapy43 is interesting, as improvement of microvascular
function after TNFa blockade may play a causative role.
There is evidence that TNFa contributes to microvascular
dysfunction. TNFa levels negatively correlate with skin
capillary recruitment even in healthy individuals24 25 and
increased production of TNFa is associated with obesity-related
insulin resistance, as well as obesity-related hypertension.25 44 A
possible mechanism involved in these microvascular distur-
bances is impaired activation of endothelial nitric oxide
synthase (eNOS). TNFa blocks the activation of eNOS, by
interfering with Akt phosphorylation, which is essential for
flow-dependent and ACh-dependent vasodilatation.45 In addi-
tion, TNFa directly degrades eNOS mRNA.46 47
In addition to specific TNFa effects on microvasculature, it is
conceivable that, in line with inflammatory driven atherogen-
esis, improvement of microvascular function was the result of a
generally decreased inflammatory ‘‘burden’’. Indeed, ESR and
CRP levels, as markers of inflammation, declined significantly
during treatment. In this regard, in 50 patients with psoriatic
arthritis (another inflammatory disease included within the
group of spondyloarthropathies) without clinically evident
cardiovascular disease, a significant correlation between CRP
level and ESR at the time of disease diagnosis and flow-mediated
endothelial dependent vasodilatation was observed.48
Correlation analyses revealed a significant correlation for
pretreatment and post-treatment ESR levels and endothelium-
dependent vasodilatation, but not for CRP. The absence of a
significant correlation between changes in CRP and vascular
function was also reported in previous studies on vascular
function in RA and AS.42 49 In our study, this may be due to
small patient numbers or indicate that, in addition to
inflammatory suppression, TNFa specific features determining
endothelial function, are important. The latter is supported by a
study showing improvement of endothelial function in patients
with RA after intravascular administration of a TNFa-blocking
agent, without concurrently affecting circulating CRP levels.50 It
is likely both mechanisms (ie, general dampening of inflamma-
tion and (other) TNFa specific effects) intertwine. The present
study design, however, is not suited to clearly differentiate
between these mechanisms.
In conclusion, we showed that patients with active AS have
vascular dysfunction at the microcirculatory level. This finding
supports the idea that AS represents a CHD risk factor. TNFa-
blocking therapy with etanercept improved microvascular
Figure 2 Correlation between changes in acetylcholine mediated
vasodilatation (post/pretreatment, relative values) and changes in
erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) levels.
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function. Further research in larger patient groups should
elucidate if this effect translates into a decrease in cardiovascular
morbidity and mortality in patients with AS.
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